Safety and Efficacy of Secukinumab in Mild Psoriasis

NCT03131570 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

23

Enrollment

OTHER

Sponsor class

Conditions

Psoriasis

Interventions

DRUG: Secukinumab
DRUG: Placebo followed by Secukinumab

Sponsor

James G. Krueger, MD, PhD

Collaborators

[object Object]